Skip to main content

Advertisement

SpringerLink
Log in

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease

  • Mini Review
  • Published:
Journal of Physiology and Biochemistry Aims and scope Submit manuscript

Abstract

End-stage renal disease (ESRD) with and/or without treatment by hemodialysis (HD) is associated with accelerated atherosclerosis, leading to cardiovascular disease (CVD) including acute coronary syndromes. Therefore, the regulation of CVD is a crucial issue for ESRD patients. Given the recent reports that paraoxonase-1 (PON-1) and ischemia-modified albumin (IMA) could predict CVD-related mortality in ESRD, the two recent biomarkers may be useful for preventive strategies for CVD. This review paper presents current data on the relationships between PON-1, IMA, and ESRD. Many studies have shown that circulating PON-1 activity is lower in ESRD patients, and we have shown that its levels increase after HD. Although circulating IMA levels can increase before HD in ESRD patients, there remains to be little data. Our pilot study has shown a significant inverse correlation between PON-1 and IMA in ESRD patients. Although the pathogenic link between PON-1 and IMA remains speculative, considering both biomarkers may provide new insights into the prevention of CVD in ESRD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aviram M, Rosenblat M (2005) Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16:393–399

    Article  PubMed  CAS  Google Scholar 

  2. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E (2001) Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 268:42–47

    Article  PubMed  CAS  Google Scholar 

  3. Bhagavan NV, Lai EM, Rios PA, Yang J et al (2003) Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49:581–585

    Article  PubMed  CAS  Google Scholar 

  4. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265–1276

    Article  PubMed  CAS  Google Scholar 

  5. Cheung AK (2009) Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 4(Suppl 1):S95–S101

    Article  PubMed  CAS  Google Scholar 

  6. Dantoine TF, Debord J, Charmes JP, Merle L et al (1998) Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9:2082–2088

    PubMed  CAS  Google Scholar 

  7. Dirican M, Akca R, Sarandol E, Dilek K (2004) Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 17:813–818

    PubMed  CAS  Google Scholar 

  8. Duarte MM, Rocha JB, Moresco RN, Duarte T et al (2009) Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 42:666–671

    Article  PubMed  CAS  Google Scholar 

  9. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A (2008) Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 6:93–107

    Article  PubMed  CAS  Google Scholar 

  10. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G (2008) Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 41:381–386

    Article  PubMed  CAS  Google Scholar 

  11. Ferretti G, Bacchetti T, Moroni C, Savino S et al (2005) Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 90:1728–1733

    Article  PubMed  CAS  Google Scholar 

  12. Gugliucci A, Lunceford N, Kinugasa E, Ogata H, Schulze J, Kimura S (2007) Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta 384:105–112

    Article  PubMed  CAS  Google Scholar 

  13. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H et al (2007) Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 377:213–220

    Article  PubMed  CAS  Google Scholar 

  14. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS (1998) Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 44:179–181

    PubMed  CAS  Google Scholar 

  15. Ikeda Y, Suehiro T, Itahara T, Inui Y et al (2007) Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 67:358–365

    PubMed  CAS  Google Scholar 

  16. Itahara T, Suehiro T, Ikeda Y, Inoue M et al (2000) Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 7:152–158

    PubMed  CAS  Google Scholar 

  17. Jurek A, Turyna B, Kubit P, Klein A (2006) LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 39:19–27

    Article  PubMed  CAS  Google Scholar 

  18. Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V et al (2001) Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 42:146–150

    PubMed  Google Scholar 

  19. Kao MP, Ang DS, Pall A, Struthers AD (2010) Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24:1–8

    Article  PubMed  CAS  Google Scholar 

  20. Kotani K, Kimura S, Kinugasa E, Ogata H, et al. (2010) Relationship between the serum levels of paraoxonase-1 and ischemia-modified albumin in subjects with end-stage renal disease on hemodialysis: a pilot study. J Comp Clin Med (in press)

  21. La Du BN, Adkins S, Kuo CL, Lipsig D (1993) Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 87:25–34

    Article  PubMed  Google Scholar 

  22. Mackness MI, Durrington PN, Mackness B (2004) The role of paraoxonase 1 activity in cardiovascular disease: potencial for therapeutic intervention. Am J Cardiovasc Drugs 4:211–217

    Article  PubMed  CAS  Google Scholar 

  23. Montagnana M, Lippi G, Tessitore N, Salvagno GL et al (2008) Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 22:59–65

    Article  PubMed  CAS  Google Scholar 

  24. Moradi H, Pahl MV, Elahimehr R, Vaziri ND (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153:77–85

    Article  PubMed  CAS  Google Scholar 

  25. Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T (2009) Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 80:306–310

    Article  PubMed  CAS  Google Scholar 

  26. Paragh G, Asztalos L, Seres I, Balogh Z et al (1999) Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83:126–131

    Article  PubMed  CAS  Google Scholar 

  27. Paragh G, Seres I, Balogh Z, Varga Z et al (1998) The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80:166–170

    Article  PubMed  CAS  Google Scholar 

  28. Piwowar A, Knapik-Kordecka M, Warwas M (2008) Ischemia-modified albumin level in type 2 diabetes mellitus—preliminary report. Dis Markers 24:311–317

    PubMed  CAS  Google Scholar 

  29. Quaschning T, Krane V, Metzger T, Wanner C (2001) Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 38(4 Suppl 1):S14–S19

    Article  PubMed  CAS  Google Scholar 

  30. Ritz E, Bommer J (2009) Cardiovascular problems on hemodialysis: current deficits and potential improvement. Clin J Am Soc Nephrol 4(Suppl 1):S71–S78

    Article  PubMed  Google Scholar 

  31. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O (2008) Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 12:471–479

    Article  PubMed  Google Scholar 

  32. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G (1996) Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 247:71–80

    Article  PubMed  CAS  Google Scholar 

  33. Sharma R, Gaze DC, Pellerin D, Mehta RL et al (2006) Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 47:493–502

    Article  PubMed  CAS  Google Scholar 

  34. Sharma R, Singh B, Mahajan M (2007) PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease. Kaohsiung J Med Sci 23:225–231

    Article  PubMed  CAS  Google Scholar 

  35. Suehiro T, Ikeda Y, Shiinoki T, Inoue M et al (2002) Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 9:133–138

    Article  PubMed  CAS  Google Scholar 

  36. Tavori H, Vaya J, Aviram M (2010) Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv Exp Med Biol 660:99–111

    Article  PubMed  CAS  Google Scholar 

  37. Turedi S, Cinar O, Yavuz I, Mentese A et al (2010) Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol 23:335–340

    PubMed  Google Scholar 

  38. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN et al (2010) Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 95:586–591

    Article  PubMed  Google Scholar 

  39. Vassalotti JA, Li S, Chen SC, Collins AJ (2009) Screening populations at increased risk of CKD: the Kidney Early Evaluation Program (KEEP) and the public health problem. Am J Kidney Dis 53(3 Suppl 3):S107–S114

    Article  PubMed  Google Scholar 

  40. Vaziri ND (2009) Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 22:644–651

    Article  PubMed  Google Scholar 

  41. Ward RA, McLeish KR (2003) Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 27:230–236

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke City, Tochigi, 329-0498, Japan

    Kazuhiko Kotani

  2. Glycation, Oxidation and Disease Laboratory, Touro University—California, Vallejo, CA, USA

    Kazuhiko Kotani & Alejandro Gugliucci

  3. Department of Laboratory Medicine and Central Clinical Laboratory, Showa University Northern Yokohama Hospital, Yokohama, Japan

    Satoshi Kimura

Authors
  1. Kazuhiko Kotani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alejandro Gugliucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhiko Kotani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kotani, K., Kimura, S. & Gugliucci, A. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. J Physiol Biochem 67, 437–441 (2011). https://doi.org/10.1007/s13105-011-0092-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13105-011-0092-4

Keywords

Search

Navigation